Schultze Anna, Ju Shinyoung, Drysdale Myriam, Mu George, Mitrani-Gold Fanny S, Logie John
London School of Hygiene and Tropical Medicine, London, UK.
GSK, Brentford, UK.
Pharmacol Res Perspect. 2025 Jun;13(3):e70124. doi: 10.1002/prp2.70124.
We report findings from three SCCS conducted to quantify the association between fluoroquinolone (FQ) use for the treatment of uncomplicated urinary tract infection (uUTI) and tendon rupture, retinal detachment, and uveitis. Female patients aged ≥ 12 years old in the Optum Clinformatics Data Mart database with an outcome of interest and exposure to either oral FQ or trimethoprim/sulfamethoxazole (SXT) in the 5 days following a newly reported uUTI during the study period (01/01/2011-02/10/2019) were included. We considered a 90-day risk window for each outcome following drug exposure. Incidence rate ratios (IRR) and 95% confidence intervals (CI) were estimated using conditional Poisson regression, adjusting for age and calendar time, incorporating SXT as an active comparator. We found little evidence of an association between FQ use compared to SXT and any of the outcomes of interest (tendon rupture: IRR = 1.01, 95% CI = 0.91-1.21; retinal detachment: IRR = 0.99, 95% CI = 0.86-1.14; and uveitis: IRR = 1.09, 95% CI = 0.97-1.22). Incorporating the active comparator using two different methods did not change conclusions. The lack of evidence for an association between short-term use of FQ and the comparator antibiotic (SXT) for the treatment of uUTI and collagen-related events also implies that there was no marked association between uUTI and these outcomes. However, power was limited, and a small increased risk cannot be ruled out. Using active comparators in SCCS can improve the robustness of studies of antibiotics and adverse events.
我们报告了三项自我控制病例系列研究(SCCS)的结果,以量化使用氟喹诺酮(FQ)治疗单纯性尿路感染(uUTI)与肌腱断裂、视网膜脱离和葡萄膜炎之间的关联。纳入了Optum临床信息数据集市数据库中年龄≥12岁的女性患者,这些患者在研究期间(2011年1月1日至2019年2月10日)新报告uUTI后的5天内有感兴趣的结局且暴露于口服FQ或甲氧苄啶/磺胺甲恶唑(SXT)。我们考虑了药物暴露后每种结局的90天风险窗口。使用条件泊松回归估计发病率比(IRR)和95%置信区间(CI),对年龄和日历时间进行调整,并将SXT作为活性对照。我们发现,与SXT相比,使用FQ与任何感兴趣的结局之间几乎没有关联证据(肌腱断裂:IRR = 1.01,95%CI = 0.91 - 1.21;视网膜脱离:IRR = 0.99,95%CI = 0.86 - 1.14;葡萄膜炎:IRR = 1.09,95%CI = 0.97 - 1.22)。使用两种不同方法纳入活性对照并未改变结论。缺乏证据表明短期使用FQ和对照抗生素(SXT)治疗uUTI与胶原相关事件之间存在关联,这也意味着uUTI与这些结局之间没有明显关联。然而,检验效能有限,不能排除存在小幅度增加的风险。在SCCS中使用活性对照可以提高抗生素与不良事件研究的稳健性。